STK11 and non-small cell lung carcinoma: Given the promising results on subsequent lines of therapy, on 11 October 2022, a new phase Ib/IIa trial (NCT05469178) was initiated to test the combination of bemcentinib and chemo-immunotherapy in the first-line setting for the treatment of STK11 mutant NSCLC patients.